Intrarectal Instillation of Clostridium difficile Toxin A Triggers Colonic Inflammation and Tissue Damage: Development of a Novel and Efficient Mouse Model of Clostridium difficile Toxin Exposure

ABSTRACT Clostridium difficile, a major cause of hospital-acquired diarrhea, triggers disease through the release of two toxins, toxin A (TcdA) and toxin B (TcdB). These toxins disrupt the cytoskeleton of the intestinal epithelial cell, increasing intestinal permeability and triggering the release of inflammatory mediators resulting in intestinal injury and inflammation. The most prevalent animal model to study TcdA/TcdB-induced intestinal injury involves injecting toxin into the lumen of a surgically generated “ileal loop.” This model is time-consuming and exhibits variability depending on the expertise of the surgeon. Furthermore, the target organ of C. difficile infection (CDI) in humans is the colon, not the ileum. In the current study, we describe a new model of CDI that involves intrarectal instillation of TcdA/TcdB into the mouse colon. The administration of TcdA/TcdB triggered colonic inflammation and neutrophil and macrophage infiltration as well as increased epithelial barrier permeability and intestinal epithelial cell death. The damage and inflammation triggered by TcdA/TcdB isolates from the VPI and 630 strains correlated with the concentration of TcdA and TcdB produced. TcdA/TcdB exposure increased the expression of a number of inflammatory mediators associated with human CDI, including interleukin-6 (IL-6), gamma interferon (IFN-γ), and IL-1β. Finally, we were able to demonstrate that TcdA was much more potent at inducing colonic injury than was TcdB but TcdB could act synergistically with TcdA to exacerbate injury. Taken together, our data indicate that the intrarectal murine model provides a robust and efficient system to examine the effects of TcdA/TcdB on the induction of inflammation and colonic tissue damage in the context of human CDI.

[1]  C. Pothoulakis,et al.  Endogenous corticosteroids modulate Clostridium difficile toxin A-induced enteritis in rats. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[2]  I. Poxton,et al.  Induction of cytokines in a macrophage cell line by proteins of Clostridium difficile. , 2012, FEMS immunology and medical microbiology.

[3]  G. Raugi,et al.  Implications of the changing face of Clostridium difficile disease for health care practitioners. , 2007, American journal of infection control.

[4]  Shinichi Nakamura,et al.  Essential Involvement of IFN-γ in Clostridium difficile Toxin A-Induced Enteritis1 , 2004, The Journal of Immunology.

[5]  W. H. Percy,et al.  Effects of purified Clostridium difficile toxin A on rabbit distal colon. , 1995, Gastroenterology.

[6]  D. Acheson,et al.  Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains , 1997, Infection and immunity.

[7]  H. Sewell,et al.  Effect of Clostridium difficile Toxin A on Human Colonic Lamina Propria Cells: Early Loss of Macrophages Followed by T-Cell Apoptosis , 1998, Infection and Immunity.

[8]  M. O'brien,et al.  Differential effects of Clostridium difficile toxins A and B on rabbit ileum. , 1987, Gastroenterology.

[9]  C. Pothoulakis,et al.  Clostridium difficile toxin A stimulates macrophage-inflammatory protein-2 production in rat intestinal epithelial cells. , 1998, Journal of immunology.

[10]  J. Bartlett,et al.  Partial purification and characterization of a cytotoxin from Clostridium difficile. , 1979, Reviews of infectious diseases.

[11]  M. Karin,et al.  Epithelial cell I kappa B-kinase beta has an important protective role in Clostridium difficile toxin A-induced mucosal injury. , 2006, Journal of immunology.

[12]  R. Guerrant,et al.  Role of inducible cyclooxygenase and prostaglandins in Clostridium difficile toxin A-induced secretion and inflammation in an animal model. , 2001, The Journal of infectious diseases.

[13]  G. Armstrong,et al.  Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. , 2010, Gastroenterology.

[14]  R. Guerrant,et al.  Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis , 1997, Clinical and diagnostic laboratory immunology.

[15]  K. Saum,et al.  Effects of Clostridium difficile toxins given intragastrically to animals , 1985, Infection and immunity.

[16]  P. Couzigou,et al.  Necrotizing enterocolitis during agranulocytosis and Clostridium difficile colitis. , 1982, Lancet.

[17]  B. Wren,et al.  Association between production of toxins A and B and types of Clostridium difficile. , 1987, Journal of clinical pathology.

[18]  C. Pothoulakis,et al.  IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. , 1997, The American journal of physiology.

[19]  M. Wilcox,et al.  Clostridium difficile: changing epidemiology and new treatment options , 2007, Current opinion in infectious diseases.

[20]  Yan Li,et al.  Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. , 2010, Gastroenterology.

[21]  J. Wallace,et al.  Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.

[22]  Y. Mahida,et al.  Monocytes Are Highly Sensitive to Clostridium difficile Toxin A-Induced Apoptotic and Nonapoptotic Cell Death , 2005, Infection and Immunity.

[23]  Julian I. Rood,et al.  Toxin B is essential for virulence of Clostridium difficile , 2009, Nature.

[24]  R Sedivy,et al.  Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. , 1995, The Journal of clinical investigation.

[25]  J. Greenson,et al.  Can ischemic colitis be differentiated from C difficile colitis in biopsy specimens? , 1997, The American journal of surgical pathology.

[26]  C. Pothoulakis,et al.  Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. , 1992, Gastroenterology.

[27]  L. Looi,et al.  Clostridium difficile-related necrotizing pseudomembranous enteritis in association with Henoch-Schonlein purpura. , 1997, Journal of pediatric gastroenterology and nutrition.

[28]  C. Pothoulakis,et al.  Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. , 1994, The Journal of clinical investigation.

[29]  D. Gerding,et al.  Optimal methods for identifying Clostridium difficile infections. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  J. Silva,et al.  Mucosal damage mediated by clostridial toxin in experimental clindamycin-associated colitis. , 1980, Gut.

[31]  R. Guerrant,et al.  Caspase and Bid Involvement in Clostridium difficile Toxin A-Induced Apoptosis and Modulation of Toxin A Effects by Glutamine and Alanyl-Glutamine In Vivo and In Vitro , 2006, Infection and Immunity.

[32]  P. Beck,et al.  Clostridium difficile-associated colitis. , 2004, Canadian family physician Medecin de famille canadien.

[33]  Jeffrey D Goldsmith,et al.  A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.

[34]  Yan Li,et al.  NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis , 2011, Inflammatory bowel diseases.

[35]  T. Gray,et al.  Effect of Clostridium difficile toxin A on human intestinal epithelial cells: induction of interleukin 8 production and apoptosis after cell detachment. , 1996, Gut.

[36]  J. Rood,et al.  The role of toxin A and toxin B in Clostridium difficile-associated disease , 2010, Gut microbes.

[37]  Ingo Just,et al.  Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. , 2008, Journal of medical microbiology.

[38]  M. Shapiro,et al.  Human intestinal epithelial and smooth muscle cells are potent producers of IL-6. , 2003, Mediators of inflammation.

[39]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[40]  C. Pothoulakis,et al.  Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. , 2007, Gastroenterology.

[41]  C. Pothoulakis,et al.  p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. , 2000, The Journal of clinical investigation.

[42]  R. Guerrant,et al.  Adenosine Deaminase Inhibition Prevents Clostridium difficile Toxin A-Induced Enteritis in Mice , 2010, Infection and Immunity.

[43]  C. Giampaolo,et al.  Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. , 1989, Gastroenterology.

[44]  M. Karin,et al.  Epithelial Cell IκB-Kinase β Has an Important Protective Role in Clostridium difficile Toxin A-Induced Mucosal Injury1 , 2006, The Journal of Immunology.

[45]  C. Pothoulakis,et al.  Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. , 1988, The Journal of clinical investigation.

[46]  C. Pothoulakis,et al.  Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats. , 1998, The American journal of physiology.

[47]  T. Savidge,et al.  Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. , 2003, Gastroenterology.

[48]  S. Calderwood,et al.  Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain , 1997, Infection and immunity.